QR Code

Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals

Abstract Background Due to promising preclinical studies and clinical case reports, Tb-161 labeled radiopharmaceuticals for targeted radionuclide therapy (TRT) have gained interest. Unlike Lu-177, Tb-161 not only emits β− particles, but also Auger and conversion electrons, which may improve the curr...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Carolline M. Ntihabose, Maryana Handula, Amber Piet, Savanne Beekman, Louise van Dalen, Negin Eskandari, Asude Aydogan, Debra Stuurman, Corrina de Ridder, Mark Konijnenberg, Yann Seimbille, Erik de Blois
Hōputu: Artigo
Reo:Inglês
I whakaputaina: SpringerOpen 2025-10-01
Rangatū:EJNMMI Radiopharmacy and Chemistry
Ngā marau:
Terbium-161
Lutetium-177
Targeted radionuclide therapy (TRT)
Radiopharmaceuticals
Active pharmaceutical ingredient (API)
Urunga tuihono:https://doi.org/10.1186/s41181-025-00390-3
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite